![]()
| As of Tuesday, December 1st: |
LATEST EARNINGS RESULTS
- Look Ahead: Markets Count Down to US Jobs Report
- FHA to Toughen Mortgage Rules in Lenders Crackdown
- Obama to Send More Troops; Seeks Afghanistan Exit
- GM Removes CEO Henderson; Whitacre is Interim Chief
- Who Were the Biggest Winners And Losers This Year?
- GE, Comcast Complete Deal Over NBC Universal: Source
- US May Raise Rates Before Jobs Recover: Fed's Plosser
- Case Closed but Woods Scrutiny Continues
- Weak Dollar Forces Mercedes to Build More in US
- Unemployment to Peak at 10.5%: Moody's Economist
- 8 Stocks to Gain on Obama's Afghan Plan: Analysts
- BofA On Proposed Changes In The Housing Bailout Program
- The Future of The Media Landscape
- November Auto Sales Muddle Along
- Busch: What Obama Won't Say Tonight
- Stick with Equities—Avoid Emerging Markets: Laszlo Birinyi
- Pfizer Chomps On A Carrot
- Predictions 2010: Technology
MOST SHARED
- Keeping America Great
- Kohlberg Kravis Bidding for Morgan Stanley's CICC Stake
- Australia Regulator Opposes Caltex-Exxon Deal
- GE, Comcast Complete Deal Over NBC Universal: Source
- Cisco Has 84% of Tandberg, Won't Extend Bid
- Toyota Takes Lead Position in Canada in November
- Australia Parliament Rejects Carbon Trade Laws
- UK Economy Turned, Inflation to Spike: BoE Economist
Pfizer Thursday reported a worse-than-expected drop in quarterly earnings on declining sales of flagship cholesterol fighter Lipitor and drugs facing generic competition, sending its shares down nearly 3 percent.
![]() |
The world's biggest drug maker said first-quarter net profit fell 18 percent to $2.78 billion, or 41 cents per share, from $3.39 billion, or 48 cents per share, a year earlier, when it took a big restructuring charge.
Excluding special items, Pfizer earned 61 cents per share. On that basis, analysts polled by Reuters Estimates had forecast 66 cents.
"The misses appear to be largely across the board, from the top line to the expenses," Morgan Stanley analyst Jami Rubin wrote in a research report. She said Lipitor sales were $300 million below her forecasts, and the main reason for the earnings shortfall.
Pfizer [PFE
Loading...
()
] said it still expects earnings this year of $2.35 to $2.45 per share, excluding special items. That would represent growth of 6.8 percent to 11.3 percent, due largely to an ongoing aggressive cost-cutting program that has already eliminated more than 10,000 jobs.
"We see potential challenges in meeting this guidance," said Rubin, who noted the disappointing quarterly results highlight "potential cash flow needs."
Global sales of Lipitor, the world's top-selling drug, fell 7 percent to $3.1 billion. U.S. sales of the medicine plunged 18 percent despite widespread publicity since January about the failure of Vytorin, a rival drug sold by Schering-Plough [PFE
Loading...
()
] and Merck [MRK
Loading...
()
], to reduce artery plaque in a closely watched trial. to reduce artery plaque in a closely watched trial.
"What's surprising to people was that despite a positive currency tailwind and some disruptions in the cholesterol market related to Vytorin, they still weren't able to pull it out" and meet the consensus earnings expectations, said Miller Tabak health care analyst Les Funtleyder.
Pfizer has been unable to come up with new blockbuster medicines to replace those that have lost patent protection, a concern that has driven its shares down to lows not seen since late 2005.
"It becomes a question of what do they do next, what do they do to reverse the negative momentum in the share price," Funtleyder said. "And the longer they wait to do something, as the valuation goes down, the less flexibility they have."
Despite Pfizer's woeful performance in recent years, many investors are clinging to its shares because of the company's industry-topping dividend.
Sales Decline
Global first-quarter revenue fell 5 percent to $11.85 billion, shy of the $12.06 billion Reuters Estimates forecast. Sales would have fallen 10 percent if not for the weak dollar, which raises the value of overseas sales when converted back to the U.S. currency.
New York-based Pfizer attributed the sales decline primarily to the loss a year ago of U.S. patent protection on blood pressure drug Norvasc and new generic competition for Zyrtec, an allergy medicine the company stopped selling in late January.
Worldwide pharmaceutical sales fell 6 percent to $10.9 billion.
Norvasc revenues were cut in half, to $513 million, while Zyrtec sales plunged 75 percent to $117 million. Arthritis treatment Celebrex edged up only 2 percent to $611 million, a marked slowdown from recent quarters. Impotence treatment Viagra grew 6 percent to $460 million.
Lyrica remained a revenue sparkplug, with sales surging 47 percent to $582 million due to its effectiveness against nerve pain and newly approved use against fibromyalgia. Sales of Sutent, another newer drug that is now the gold standard for kidney cancer, rose 86 percent to $190 million.
Champix, which helps smokers quit, was another bright spot amid the bleak earnings report, as its sales jumped 71 percent to $277 million.
Pfizer shares were down 60 cents, or 2.8 percent at $20.50 in early New York Stock Exchange trading.
- Deere Reports Quarterly Net Loss, Revenue Falls
Deere & Co, the world's largest maker of tractors and harvesters, reported a quarterly net loss on Wednesday on weak equipment sales and a series of one-time charges.
- TiVo Reports Quarterly Loss but Matches Forecasts
TiVo announced a quarterly loss that matched analysts' forecasts, but its sales topped expectations.
- Hewlett-Packard Profit Rises, Matches Guidance
Hewlett-Packard said a strong performance in China and improved profit margins in its services business helped drive quarterly earnings 14 percent higher.
- Deere Reports Quarterly Net Loss, Revenue Falls
- Analog Devices Results Beat Expectations; Shares Rise
Analog Devices reported a quarterly profit that fell from a year ago but topped Wall Street's expectations, sending shares higher in extended trading.
- Analog Devices Results Beat Expectations; Shares Rise
- Tyson Food Profit Beats Estimates
- Horton Results Miss Estimates, Shares Drop
- Dell Shares Smacked as Earnings, Sales Miss Forecasts
- Gap Reports Earnings in Line With Forecasts
- Intuit Posts Narrower-Than-Expected Loss
- Sears Posts Second Consecutive Quarterly Loss
- BJ's Wholesale Profit Falls, Hurt by Falling Food Prices
- Salesforce Profit Beats Forecasts, but Shares Fall
- Autodesk Shares Fall on Disappointing Outlook
- Home Depot Profit Beats; Says Markets Under Pressure
- Target Third Quarter Profit Up, Cautious on Fourth
- Weak US Housing Market Drags on Lowe's Profit
- JC Penney Profit Falls, but Shares Up on Forecast
- Disney Profit, Sales Top Forecasts; Shares Jump
- Nordstrom Earnings Miss Forecasts; Shares Take Hit







